The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

PURPOSE: This multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHCC). METHODS: Patients with histologically confirmed aHCC wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Qian, Han, Chun, Ye, Sisi, Li, Juan, Shao, Guoliang, Bai, Yuxian, Xu, Aibing, Sun, Meili, Wang, Wei, Wu, Jian, Huang, Ming, Song, Lijie, Huang, Luke, Liu, Ting, Liu, Wei, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Bai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627805/
https://www.ncbi.nlm.nih.gov/pubmed/37942328
http://dx.doi.org/10.3389/fimmu.2023.1238667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627805/
https://www.ncbi.nlm.nih.gov/pubmed/37942328
http://dx.doi.org/10.3389/fimmu.2023.1238667

Ejemplares similares